References
- Diehl V, Franklin J, Pfreundschuh M, et al Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386–2395.
- Engert A, Diehl V, Franklin J, et al Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 Study. J Clin Oncol 2009. epub ahead of print.
- Ballova V, Ruffer JU, Haverkamp H, et al A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005;16:124–131.
- Borchmann P, Engert A, Pluetschow A, et al Dose-intensified combined modality treatment with 2 cycles of BEACOPPescalated followed by 2 cycles of ABVD and involved-field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IF-RT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) Blood 2008;112:367 (Abstract).
- Ruffer JU, Ballova V, Glossmann J, et al BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkin's disease – results of the German Hodgkin Study Group. Leuk Lymphoma 2005;46:1561–1567.
- Sieniawski M, Franklin J, Nogova L, et al Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007;25:2000–2005.
- Schmitz N, Pfistner B, Sextro M, et al Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065–2071.
- Cavalieri E, Matturro A, Annechini G, et al Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma 2009;50:1803–1808.
- Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878–1886.
- Myrehaug S, Pintilie M, Tsang R, et al Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49:1486–1493.